Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) plunged ~21% in the morning hours on Wednesday after the biotech fell short of ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would ...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) plummeted 19% lower on Wednesday noon after the company reported ...

Absci reported quarterly losses of 25 cents per share which missed the analyst consensus estimate of 23 cents per share. This ...

Reports Q4 revenue $2.6M, consensus $3.35M.”With commercial preparations underway, we believe we are well positioned to launch TNX-102 SL for ...

Shares of Tonix Pharmaceuticals Holding fell after the company logged lower sales and another net loss in the fourth quarter. The stock declined 6.9%, to $19.12, in after-hours trading Tuesday. Shares ...

Tonix Pharmaceuticals shares have surged 115% since Monday's open. Tonix this week announced data regarding its fibromyalgia ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.00%, which has investors questioning if this is right ...

Tonix expects to have sufficient cash to fund operations beyond the August 15, 2025 PDUFA date for TNX-102 SL and its anticipated Q4 2025 launch. The company reported $98.8 million in cash as of ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and ...